Literature DB >> 8641311

Relationship between outer membrane protein profiles and resistance to ceftazidime, imipenem, and ciprofloxacin in Pseudomonas aeruginosa isolates from bacteremic patients.

C Gimeno1, D Navarro, F Savall, E Millás, M A Farga, J Garau, R Cisterna, J García-de-Lomas.   

Abstract

Outer membrane protein (OMP) profiles of 122 Pseudomonas aeruginosa isolates recovered from the blood of bacteremic patients were analyzed to relate alterations in the expression of OMPs with porin activity to resistance to imipenem, ceftazidime, and ciprofloxacin. Imipenem-resistant isolates lacked or expressed reduced amounts of porin OprD. In contrast, alterations of OMP profiles were absent in most ceftazidime-resistant isolates. Six of 12 ciprofloxacin-resistant isolates had normal OMP profiles. The remaining isolates showed alterations in the expression of either OprC, OprF, or OprD. In addition, imipenem- and ceftazidime-resistant isolates displayed a beta-lactamase activity compatible with that of a group 1 chromosomal cephalosporinase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8641311     DOI: 10.1007/bf01586192

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  21 in total

1.  Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa.

Authors:  D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa.

Authors:  J Trias; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

Review 3.  Characterization of beta-lactamases.

Authors:  K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

4.  Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections.

Authors:  J P Quinn; E J Dudek; C A DiVincenzo; D A Lucks; S A Lerner
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

Review 5.  Extended-spectrum beta-lactamases.

Authors:  A Philippon; R Labia; G Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

6.  Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa.

Authors:  X Y Zhou; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

7.  Mechanism of imipenem resistance acquired by three Pseudomonas aeruginosa strains during imipenem therapy.

Authors:  U Vurma-Rapp; F H Kayser; K Hadorn; F Wiederkehr
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-08       Impact factor: 3.267

Review 8.  Beta-lactamases: current situation and clinical importance.

Authors:  J Garau
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

9.  Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa.

Authors:  T Yoshida; T Muratani; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

Review 10.  beta-Lactam resistance in gram-negative bacteria: global trends and clinical impact.

Authors:  C C Sanders; W E Sanders
Journal:  Clin Infect Dis       Date:  1992-11       Impact factor: 9.079

View more
  1 in total

1.  In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.

Authors:  Hannah M Wexler; Adrian E Engel; Daniel Glass; Calida Li
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.